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Abstract. TheWorld Health Organization (WHO) estimates that 40% of children in low-income countries are anemic.
Therefore, iron supplements are recommended byWHO in areaswith high anemia rates. However, some studies have set
into question the beneﬁts of iron supplementation in malaria-endemic regions. In Benin, a west African country with high
prevalence of anemia and malaria, no iron supplements are given systematically to infants so far despite the WHO
recommendations. In this context, we wanted to investigate the effect of iron levels during the ﬁrst year of life on malarial
risk in Benin considering complementary risk factors. We followed 400 women and their offspring between January 2010
and June 2012 in Allada (Benin). Environmental, obstetric, and numerous clinical, maternal, and infant risk factors were
considered. In multilevel models, high iron levels were signiﬁcantly associated with the risk of a positive blood smear
(adjusted odds ratio = 2.90, P < 0.001) and Plasmodium falciparum parasitemia (beta estimate = 0.38, P < 0.001). Infants
with iron levels in the lowest quartile were less likely to have a positive blood smear (P< 0.001), and the risk increasedwith
higher iron levels. Our results appeal for additional evaluation of the effect of different doses of iron supplements on the
infant health status, including malaria incidence. Thus, the health status of infants should be compared between cohorts
where iron is given either for prevention or anemia treatment, to better understand the effect of iron supplements on infant
health.
INTRODUCTION
Infant health morbidity in sub-Saharan Africa is mainly
driven by infectious diseases and nutritional deﬁciencies.1
Indeed, malaria and anemia (mainly due to iron deﬁciency [ID])
contribute to enhance signiﬁcantly the disease burden among
African infants.2 The World Health Organization (WHO) esti-
mates indicate there were over 214 million new malaria cases
and 438,000 deaths in 2015.3 In addition, malaria causes
anemia, which entails severe long-term consequences for the
development of the children.4 Anemia is the second leading
cause of disability worldwide,5 and both malaria and anemia
harmmainly children under 5 years of age. For these reasons,
public health strategies have been developed to tackle both
diseases simultaneously.
WHO recommends the administration of 12.5 mg iron and
50μg folic acid daily between 6 and 12months of age to tackle
anemia.6 However, in Benin, this policy has not been imple-
mented so far. In general, Beninese pediatricians give a pre-
ventive treatment consisting of 10 mg/kg iron per day starting
at 6months of age until 5 years of age. These supplements are
given during 2 months followed by a 4-month period without
treatment. With regard to malaria in children, WHO recom-
mends at present the use of insecticide-treated nets and/or
indoor residual spraying for vector control, andprompt access
to diagnostic testing of suspected malaria and treatment of
conﬁrmed cases.
As both diseases overlap geographically and they harm
mainlychildrenunder5 yearsofage, it is essential to analyze the
association between iron levels and malaria risk in infants. Old
clinical trials reported increased susceptibility among iron-
supplemented children,7–9 and ID has been associated with
reducedmalariaoddsamongpregnantwomenand infants.10,11
However, iron supplements are not signiﬁcantly associated
with increased malaria risk in recent clinical trials or in the 2016
Cochrane review.12 Furthermore, one of the most recent
Cochrane reviews outlines the scarcity of prospective cohorts
analyzing the iron–malaria association during infancy.11
For these reasons, we investigated the effect of the in-
fants’ iron levels during the ﬁrst year of life on malarial risk
in infants taking into account complementary information on
pregnancy-associated malaria (PAM), environmental, socio-
economic, and clinical indicators and comorbidities to better
understand malaria risk factors in the context of the present
malaria control strategies.
MATERIALS AND METHODS
A prospective cohort of 400 infants was followed from birth
to 12months of age in the context of theAnemia in Pregnancy:
Etiology andConsequences (APEC) study. The APEC study
is an ancillary survey nested within the Malaria in Preg-
nancy Preventive Alternative Drugs (MiPPAD) trial in Benin
(http://clinicaltrials.gov/ct2/show/NCT00811421). This
study was conducted in three clinics in the district of Allada,
between January 2010 and May 2012. Allada is a semirural
area of 91,778 inhabitants located 50 km north of Cotonou
(Benin). Plasmodium falciparum is the species responsible
for the majority of infections.
Complete details of MiPPAD are presented elsewhere,13
but brieﬂy, MiPPAD was a randomized trial comparing the
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efﬁcacy and safety of intermittent preventive treatment in
pregnancy (IPTp) with sulfadoxine–pyrimethamine (SP;
1,500/75 mg per dose) and meﬂoquine (MQ; 15 mg/kg per
dose). At delivery, placenta was examined to analyze P. fal-
ciparum parasite infestation. Clinical data of the infants were
collected during systematic visits at 6, 9, and 12 months
of age. In case of sickness, infants were evaluated and,
if necessary, treated according to Beninese guidelines
(artemether–lumefantrine for uncomplicated malaria; paren-
teral artesunate or quinine for complicated malaria).
In the unscheduled visits, clinical and biological examina-
tions were performed following the same protocol as sys-
tematic visits. All drugs prescribed to the infants during the
follow-up were free of charge.
According to the protocol of the APEC substudy, anthro-
pometric measures and an extensive clinical examination
were performed during the visits. In addition, 8 mL of venous
bloodwere collected at each visit. Hemoglobin, serum ferritin,
C-reactive protein (CRP), vitamin B12, and folate levels were
assessed. A container was also given to the women to collect
the infant’s stools in search of intestinal helminths. The con-
tainers were collected the following day by the study nurses
within the ﬁrst 6 hours after emission. Microbiological exami-
nationswere performed as follows: Lambare´ne´ techniquewas
used to assess malaria infection.14 It consists of spreading a
calibrated 10 μL amount of blood on a slide’s rectangular area
of 1.8 cm2 (1.8 × 1 cm). The slide was stainedwith Giemsa and
read at a magniﬁcation of 1,000× with an oil immersion lens.
To assess parasite density (in parasites/μL), a multiplication
factor was applied to the average parasitemia/ﬁeld. Amalaria-
infected placenta was deﬁned as a placenta with a positive
smear at birth. Helminthic infestations were assessed using
the Kato-Katz concentration method (VestergaardFrandsen
kit®, NewDelhi, India). In case of inﬂammation (CRP> 5mg/L),
serum ferritin was adjusted following the corrections recom-
mended by Thurnham and others in their meta-analysis,15 to
avoid the extrinsic effect of inﬂammation on serum ferritin
levels. More precisely, we multiplied serum ferritin by 0.76 in
the presence of Plasmodium without inﬂammation, and we
multiplied serum ferritin by 0.53 in case of concurrent Plas-
modium infection and inﬂammation.
We used rain quantity as a surrogate for the risk of expo-
sure to anopheline bites. In the semirural area of Allada,
malaria has a perennial transmission pattern with two trans-
mission peaks corresponding to the rainy seasons in April–
July and October–November. According to literature, rainfall
can be a valid surrogate for anopheline risk.16–18 Because of
the anopheline timeliness, rainfall quantity was calculated
as the mean rain volume of the 7 days prior to the 2 weeks
before theconsultation.19 Even if the clinicswere close toeach
other, rainfall quantity was independently assessed for each
visit and each clinic.
Socioeconomic statuswasassessedusingasocioeconomic
index created in a two-step process. First, socioeconomic
items (home possession of latrines, electricity, a refrigerator, a
television, a vehicle with at least two wheels, the mother being
married, and the mother working outside the home) were plot-
ted into a multiple correspondence analysis.20,21 Then, two
predictors were created to synthesize the information, and as
the ﬁrst captured the large majority of the information, it was
withheld as the socioeconomic index. We used this approach
because it allows us to create a synthetic objective index of
socioeconomic itemswithout any a priori on theweight of each
of the elements of the index.
Data were double entered and analyzed with ACCESS
2003, and STATA 12.0 Software (Stata Corp, College Sta-
tion, TX). Then, exploratory and univariate analyses were
performed to assess the association of all variables with
both infant positive smear and peripheral P. falciparum den-
sity at each visit (systematic or unscheduled visit). χ2 and
FIGURE 1. Study proﬁle.
TABLE 1
Clinical and biologic results of the infants at birth
Mean or proportion (95% CI)
Sex of the infants Male: 183 (46.9%)
Female: 207 (53.1%)
Gestational age at
birth (weeks) (Ballard score)
38.1 (37.8; 38.4)
Weight (g) 3,033.5 (2,992; 3,075)
Low birthweight (%)
(birthweight < 2,500 g)
9 (6.2; 11.9)
Plasmodium falciparum–infected
placenta (%)
10.9 (7.8; 13.9)
Hemoglobin (g/L) 139 (136.9; 141)
Serum ferritin (μg/L) 182.6 (165.5; 199.7)
Folate (ng/L) 16.5 (12.6; 20.4)
CI = conﬁdence interval.
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Kruskal–Wallis tests were used in the univariate analyses. For
time-dependent variables, univariate analyses were per-
formed using a random intercept model at the infant level.
Then, all variables withP values < 0.2 were included in either a
logistic or a linear multivariate multilevel model with a random
intercept and slope at the infant level including all visits (sys-
tematic and unscheduled visits) for each infant, to explore the
determinants of the probability of having a positive smear or
peripheral P. falciparum parasitemia, respectively. More pre-
cisely, a random slope was applied to the infant age, as the
effect of the variables might differ between the infants. The
statistical signiﬁcance in the ﬁnal multivariate models was set
to P < 0.05 (two-sided tests). To evaluate the possible diverse
effect of different iron levels on malaria risk, we ran the same
multilevel model considering the different quartiles of cor-
rected ferritin.
The study was conducted in the context of a clinical trial.
According to the International Committee of Medical Journal
Editors guidelines, our clinical trial was registered as follows:
EDCTP-IP.07.31080.002, MiPPAD study “Malaria in Preg-
nancy Preventive Alternative Drugs,” (http://clinicaltrials.
gov/ct2/show/NCT00811421). This study was approved by
the EthicsCommittee of the Faculty ofMedicine of Cotonou. It
was explained in the local language to the mothers and their
voluntary consent was obtained before enrollment.
RESULTS
Between January 2010 and June 2012, 400 mother–infant
pairs were included in the cohort. In all, 353 infants
continued to be followed up until the ﬁrst systematic visit at
6 months, 341 until the second visit at 9 months, and 324
completed the 12 month follow-up (Figure 1). Even though
10.9%of the placentaswere infected byPlasmodium, no cord
blood infection by Plasmodium was detected at the micro-
scopic examination. The main characteristics of the infants at
birth are presented in Table 1.
During the ﬁrst year of life, 159 infants (40%) had at least one
malarial episode, with a range of 0–4 positive smears taking
into account both systematic and unscheduled visits. More
precisely, 241 infants (60.25%) had no positive blood smear
during theentire follow-up, 88 (22%)hadone, 50 (12.50%)had
two, 18 (4.5%) had three, and three (0.75%) had four positive
blood smears during follow-up. The clinical and biological
characteristics of the infants at the systematic visits are
summarized in Table 2. The proportion of infants with a posi-
tive smear at the systematic visits remained constant along
the follow-up (around 12%of the infantswere infected at each
systematic visit). However, P. falciparum parasitemia did
change signiﬁcantly during the ﬁrst year of life. Among infants
with at least one positive smear, the mean P. falciparum
density was 57,699.87 parasites/mm3 (95% conﬁdence in-
terval [CI] = 17,585; 97,815) at 6 months, 154,596.6 para-
sites/mm3 (95% CI = 45,882; 263,311) at 9 months, and
81,190.45 parasites/mm3 (95% CI = 26,020; 136,361) at
12months of age. The geometricmean values ofP. falciparum
density were 8,250.784 parasites/mm3 (95% CI = 3,723;
18,285) at 6months,18,595.95parasites/mm3 (95%CI=8,676;
39,859) at 9months, and 11,448.56 (95%CI = 5,491; 23,869)
at 12 months of age among infants with a positive smear.
In parallel, the mean hemoglobin values increased slightly,
though not signiﬁcantly, through the follow-up (102.1, 102.9,
and 103.6 g/L at the 6-, 9-, and 12-month systematic visits,
respectively).
TABLE 2
Clinical and biologic results of the infants during the follow-up period (6, 9, and 12 months)
Characteristics
6 months (N = 327) 9 months (N = 325) 12 months (N = 324)
Mean or proportion (95% CI) Mean or proportion (95% CI) Mean or proportion (95% CI)
Plasmodium falciparum infection (%) 12.06 (8.45; 15.68) 12.00 (8.28; 15.52) 12.34 (8.70; 15.99)
Parasite density (nb/mm3) 6,960.862 (1,869.05; 12,052.19) 18,392.52 (4,791.55; 31,993.49) 9,794.40 (2,764.46; 16,824.35)
Hemoglobin (g/L) 102.22 (100.55; 103.88) 102.91 (101.32; 104.50) 103.80 (102.14; 105.47)
Anemia (%) (Hb < 110 g/L) 66.99 (61.74; 72.23) 69.81 (64.65; 74.96) 64.86 (59.54; 70.17)
Mild anemia (%) (Hb = 100–109 g/L) 31.41 (26.23; 36.59) 34.09 (28.77; 39.41) 36.42 (31.06; 41.78)
Moderate anemia (%) (Hb = 80–109 g/L) 28.53 (23.48; 33.56) 30.52 (25.34; 35.69) 21.73 (17.13; 26.32)
Severe anemia (%) (Hb < 80 g/L) 7.05 (4.19; 9.90) 5.19 (2.70; 7.69) 6.70 (3.92; 9.50)
Corrected serum ferritin (μg/L) 604.58 (507.64; 701.52) 455.37 (384.27; 526.48) 436.16 (350.42; 521.90)
Iron deﬁciency (%) (corrected SF < 15 μg/L) 16.09 (8.21; 23.97) 29.63 (20.88; 38.38) 34.28 (25.06; 43.52)
CI = conﬁdence interval; Hb = hemoglobin; SF = serum ferritin.
TABLE 3
Multilevel model on factors associated with having positive blood smears during the ﬁrst year of life
Factor aOR (95% CI) P value
Infant factors
Ferritin corrected on inﬂammation (logarithm of μg/L) 2.90 (1.68; 4.98) < 0.001
Inﬂammatory process (CRP > 5 mg/L) 4.41 (2.51; 7.74) < 0.001
Age 1–4 months (reference)
Age 4–8 months 4.63 (0.65; 33.16) 0.13
Age 8–12 months 3.52 (0.41; 30.04) 0.25
Demographic and environmental factors
Low socioeconomic index 1.14 (0.88; 1.47) 0.33
Rain volume (mm) 1.04 (0.99; 1.10) 0.14
aOR=adjustedodds ratio; CI = conﬁdence interval; CRP=C-reactiveprotein. Random intercept at the infant level. Randomslope for the ageof the infants. Analysis on 906blood smears from344
infants.
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Iron indicators decreased through the follow-up. The mean
ferritin levels decreased after the 6-month visit from 605 μg/L
(95% CI = 508; 702) to 455 μg/L (95% CI = 384; 526) at
9 months, and then decreased again to 436 μg/L (95% CI =
350; 522) at 12 months. ID increased, from 16% at 6 months,
to 29% at 9 months, and up to 34% at 12 months of age.
During the ﬁrst year of life, malaria rates and P. falciparum
parasitemia were determined by clinical, environmental, and
socioeconomic factors. The risk factors for malaria and
P. falciparum parasite density are presented in Table 3
and Table 4, respectively.
There were no statistical differences in the number of pos-
itive smears or in P. falciparum density during the ﬁrst year of
life of the infant dependingon the placentalmalaria status. The
IPTp regimen of the mothers (either SP or MQ) was not as-
sociated with the number of positive smears or with the par-
asite density of the infants.
The infant iron levels (log of ferritin corrected on inﬂam-
mation) were signiﬁcantly associated with the risk of a posi-
tive blood smear (adjusted odds ratio [aOR] = 2.90, 95%
CI = 1.68; 4.98, P < 0.001) and P. falciparum parasite den-
sity (beta estimate = 0.38, 95% CI = 0.21; 0.55, P < 0.001)
during the ﬁrst year of life. Infants with ID were signiﬁcantly
less likely to have a positive blood smear and a high
P. falciparum density (P = 0.01 in both cases). Thus, the
ongoing inﬂammatory status of the infant (CRP > 5mg/L) was
signiﬁcantly associated with an increased risk of a positive
blood smear (aOR = 4.41, 95%CI = 2.51; 7.74, P < 0.001) and
to a higher P. falciparum parasite density (beta estimate = 0.69,
95% CI = 0.50; 0.88, P < 0.001). The presence of other para-
sites such as intestinal helminths was not signiﬁcantly asso-
ciated with increased risk of a positive smear or with
P. falciparum parasitemia. Infants between 4 and 8 months of
age had a signiﬁcantly higher P. falciparum parasitemia
compared with the other age periods (infants between 0 and
4 months, and infants between 8 and 12 months). The rain
quantity (representing the anopheline risk) was not associated
with increased risk of a positive smear or with increased
P. falciparum parasitemia.
Finally,we further investigated thedifferences inmalaria risk
factors considering the different quartiles of iron levels in in-
fants to evaluate the possible different effects of iron on
malaria risk depending on the different iron levels. Indeed,
infants with iron levels in the three upper quartiles had signif-
icantly higher risk of having malaria during the ﬁrst year of life
(Table 5). Infants with iron levels in the upper quartiles had
signiﬁcantly higher P. falciparum parasite density.
DISCUSSION
In this study, high iron levels were signiﬁcantly associated
with malaria incidence and with parasite density in infants
during the ﬁrst year of life in a prospective longitudinal
cohort, considering environmental, socioeconomic, and
PAM factors. Iron levels, measured by ferritin adjusted on
inﬂammation, a consistent indicator of iron,22,23 were sig-
niﬁcantly associated with a positive blood smear and
P. falciparum parasitemia. Furthermore, this association was
TABLE 4
Multilevel model on factors associated with Plasmodium falciparum parasitemia (in logarithm) during the ﬁrst year of life
Factor Beta estimate (95% CI) P value
Infant factors
Ferritin corrected on inﬂammation (logarithm of μg/L) 0.38 (0.21; 0.55) < 0.001
Inﬂammatory process 0.69 (0.50; 0.88) < 0.001
Age of the infant (1–4 months (reference))
Age of the infant 4–8 months 0.27 (0.01; 0.52) 0.04
Age of the infant 8–12 months 0.07 (_0.18; 0.32) 0.58
Demographic and environmental factors
Low socioeconomic index 0.13 (_0.08; 0.11) 0.78
Rain volume (mm) 0.01 (_0.01; 0.04) 0.28
CI = conﬁdence interval. Random intercept at the infant level. Random slope for age of the infant. Analysis on 905 blood smears of 344 infants.
TABLE 5
Multilevel model on factors associatedwithmalaria risk during the ﬁrst year of life depending on the different iron levels (905 blood smears from344
infants)
Factor
Multilevel model on the
positive blood smear
Multilevel model on
Plasmodium falciparum parasitemia
aOR (95% CI) P value Beta estimate (95% CI) P value
Infant factors
Ferritin corrected on inﬂammation (logarithm of μg/L)
1st quartile
(Reference)
Ferritin corrected on inﬂammation 2nd quartile 2.33 (1.04; 5.21) 0.04 0.16 (_0.08; 0.40) 0.19
Ferritin corrected on inﬂammation 3rd quartile 2.88 (1.30; 6.37) < 0.01 0.26 (0.02; 0.50) 0.03
Ferritin corrected on inﬂammation 4th quartile 4.15 (1.89; 9.15) < 0.001 0.45 (0.21; 0.70) < 0.001
Inﬂammatory process 4.21 (2.46; 7.21) < 0.001 0.69 (0.50; 0.88) < 0.001
Age of the infant (1–4 months (reference))
Age of the infant 4–8 months 3.75 (0.53; 26.68) 0.19 0.28 (0.02; 0.53) 0.04
Age of the infant 8–12 months 3.13 (0.37; 26.81) 0.30 0.08 (_0.17; 0.33) 0.52
Demographic and environmental factors
Low socioeconomic index 1.16 (0.87; 1.55) 0.35 0.01 (_0.08; 0.11) 0.77
Rain volume (mm) 1.04 (0.99; 1.10) 0.16 0.01 (_0.01; 0.04) 0.30
aOR = adjusted odds ratio; CI = conﬁdence interval.
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signiﬁcant even after adjustment on inﬂammatory status. ID
was associated with a signiﬁcant protection against malaria
through the entire follow-up. More precisely, infants with iron
levels in the ﬁrst quartile seemed to be signiﬁcantly protected
against malaria.
The mothers of these infants were also followed during
pregnancy.Weassessed theirmalarial risk taking into account
pregnancy parameters, comorbidities, environmental and
socioeconomic indicators, and their IPTp regime.24 Among
these women, high iron levels (measured by the log10 of fer-
ritin corrected on inﬂammation) were also signiﬁcantly asso-
ciated with increased risk of a positive blood smear (aOR =
1.75; 95% CI [1.46; 2.11]; P < 0.001) and high P. falciparum
density (beta estimate = 0.22; 95% CI [0.18; 0.27]; P < 0.001)
during the entire pregnancy follow-up period. Furthermore,
iron-deﬁcient women were signiﬁcantly less likely to have a
positive blood smear and highP. falciparum density (P< 0.001
in both cases).
Indeed, ID was associated with a signiﬁcant degree of
protection from episodes of clinical malaria in a cohort of
young children living on the Kenyan coast.25 Nevertheless,
results on the effect of iron levels on malaria differ in the
context of clinical trials with iron supplements. In a speciﬁc
Cochrane review,12 no signiﬁcant difference in clinical malaria
episodes was detected between children supplemented with
iron alone and those receiving a placebo (risk ratio [RR] = 0.93,
95% CI = 0.87; 1.00). However, the effect of ID was not
assessed, and solid preventive measures against malaria
were implemented in the clinical trials. Indeed, an increased
risk of malaria with high iron levels was observed in trials
that did not provide malaria surveillance and treatment, and
the risk of malaria parasitemia was higher with high iron
levels in a previous version of the Cochrane review (RR = 1.13,
95% CI = 1.01; 1.26).11 Furthermore, in numerous studies
included in the meta-analysis, iron was seldom determined
longitudinally.
Malaria physiopathology could explain the increased
malarial risk associatedwith elevated iron levels. In effect, iron
inhibits the synthesis of nitric oxide by inhibiting the expres-
sion of inducible nitric oxide synthase at the host level, and
thereby interferes with macrophage-mediated cytotoxicity
against Plasmodium.26 Furthermore, non-transferrin bound
iron is associatedwith the severity ofmalaria,27–29With regard
to theparasite itself,Plasmodiumhas thecapacity of acquiring
iron in a transferrin-independent pathway,30 and it has a
vacuolar iron-transporter homologue that acts as a detoxi-
ﬁer.31 Indeed, in in vitro parasite cultures,P. falciparum infects
iron-deﬁcient erythrocytes less efﬁciently comparedwith iron-
replete human erythrocytes.32
In any case, it is essential to consider that iron supplements
have undeniable beneﬁts for infants. A 2013 meta-analysis
showed supplementation was associatedwith a reduced risk of
anemia, of ID, and of iron deﬁciency anemia.33 Epidemiological
studies have linked ID to several adverse consequences of child
development, including impairments in cognitive, emotional,
andmotor development.4 Aspondering the advantages and risk
of iron supplements is daunting because they are not epidemi-
ologically quantiﬁable, the implementation of malaria protective
strategies should be seriously encouraged.
CONCLUSIONS
Malaria risk during the ﬁrst year of life is also associatedwith
high ferritin levels in a prospective longitudinal cohort
considering complementary risk factors. Our data also sug-
gest that malaria risk increases with higher ferritin levels. In-
deed, the interaction between iron and malaria is complex
because of the iron requirements during infancy and the fact
TABLE 6
Univariate analyses on factors associated with having positive blood smears during the ﬁrst year of life
Factor aOR (95% CI) P value
Infant factors
Ferritin corrected on inﬂammation (logarithm of μg/L) 2.53 (1.61; 3.99) < 0.001
Inﬂammatory process (CRP > 5 mg/L) 4.11 (2.52; 6.70) < 0.001
Age 1–4 months (reference)
Age 4–8 months 1.96 (1.13; 3.41) 0.02
Age 8–12 months 2.02 (1.02; 3.98) 0.04
Demographic and environmental factors
Low socioeconomic index 1.09 (0.90; 1.33) 0.38
Rain volume (mm) 1.03 (0.99; 1.07) 0.08
aOR=adjustedodds ratio; CI = conﬁdence interval; CRP=C-reactiveprotein. Random intercept at the infant level. Randomslope for the ageof the infants. Analysis on 906blood smears from344
infants.
TABLE 7
Univariate analyses on factors associated with Plasmodium falciparum parasitemia (in logarithm) during the ﬁrst year of life
Factor Beta estimate (95% CI) P value
Infant factors
Ferritin corrected on inﬂammation (logarithm of μg/L) 0.38 (0.22; 0.57) < 0.001
Inﬂammatory process 0.71 (0.52; 0.90) < 0.001
Age of the infant (1–4 months [reference])
Age of the infant 4–8 months 0.19 (_0.02; 0.41) 0.08
Age of the infant 8–12 months 0.10 (_0.10; 0.31) 0.33
Demographic and environmental factors
Low socioeconomic index 0.03 (_0.08; 0.13) 0.62
Rain volume (mm) 0.02 (_0.01; 0.04) 0.09
CI = conﬁdence interval. Random intercept at the infant level. Random slope for age of the infant. Analysis on 905 blood smears of 344 infants.
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that iron contributes to the parasite growth. These results
appeal for additional epidemiological studies to evaluate the
effect of different doses of iron supplements on the infant
infectious and hematological outcomes. Complementary
interventional data are needed to determine the beneﬁts and
risks of differently dosed iron supplements to ascertain their
impact on infant health in malaria-endemic regions. Finally,
the epidemiological comparison between cohorts in which
iron is given as preventive intervention, and cohorts in which
iron is given for anemia or ID treatment should also be
analyzed.
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